It has been long known that an inverse correlation exists between PTEN abundance and AKT pathway activity in patients with hematological malignancies (48), and reducing AKT signaling in LSCs through upregulating PTEN protein level has been previously suggested as a potential therapeutic approach for treating AML (37). This evidence concerns the gene PTEN and hematologic disorder.